JP6805172B2 - ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 - Google Patents
ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 Download PDFInfo
- Publication number
- JP6805172B2 JP6805172B2 JP2017557324A JP2017557324A JP6805172B2 JP 6805172 B2 JP6805172 B2 JP 6805172B2 JP 2017557324 A JP2017557324 A JP 2017557324A JP 2017557324 A JP2017557324 A JP 2017557324A JP 6805172 B2 JP6805172 B2 JP 6805172B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- mixture
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*N(*N(*)*)C(c(*(C)c1)**c1-c1n[o]c(C(F)(F)F)n1)=O Chemical compound C*N(*N(*)*)C(c(*(C)c1)**c1-c1n[o]c(C(F)(F)F)n1)=O 0.000 description 2
- MLTZNSHLFMSOPY-HNNXBMFYSA-N C[C@@H](CCC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O)CN1CCC2(CC2)CC1 Chemical compound C[C@@H](CCC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O)CN1CCC2(CC2)CC1 MLTZNSHLFMSOPY-HNNXBMFYSA-N 0.000 description 1
- NLDCYGWSPPNJSB-GFCCVEGCSA-N C[C@H](C(N(CC1)Cc2c1cccc2)=O)NC(OC(C)(C)C)=O Chemical compound C[C@H](C(N(CC1)Cc2c1cccc2)=O)NC(OC(C)(C)C)=O NLDCYGWSPPNJSB-GFCCVEGCSA-N 0.000 description 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N C[C@H](C(O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@H](C(O)=O)NC(OC(C)(C)C)=O QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 1
- KUENUWACNZYNKC-SNVBAGLBSA-N C[C@H](CN(CC1)Cc2c1cccc2)N Chemical compound C[C@H](CN(CC1)Cc2c1cccc2)N KUENUWACNZYNKC-SNVBAGLBSA-N 0.000 description 1
- ATPMCQLSQHGRHW-CYBMUJFWSA-N C[C@H](CN(CC1)Cc2c1cccc2)NC(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)Cc2c1cccc2)NC(OC(C)(C)C)=O ATPMCQLSQHGRHW-CYBMUJFWSA-N 0.000 description 1
- OYXHJSOZEXCCIB-CQSZACIVSA-N C[C@H](CN(CC1)Cc2c1cccc2)NC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O Chemical compound C[C@H](CN(CC1)Cc2c1cccc2)NC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O OYXHJSOZEXCCIB-CQSZACIVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158363P | 2015-05-07 | 2015-05-07 | |
| US62/158,363 | 2015-05-07 | ||
| PCT/US2016/031335 WO2016179554A1 (en) | 2015-05-07 | 2016-05-06 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515489A JP2018515489A (ja) | 2018-06-14 |
| JP2018515489A5 JP2018515489A5 (enExample) | 2019-06-13 |
| JP6805172B2 true JP6805172B2 (ja) | 2020-12-23 |
Family
ID=57218014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557324A Active JP6805172B2 (ja) | 2015-05-07 | 2016-05-06 | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10053434B2 (enExample) |
| EP (1) | EP3291810B1 (enExample) |
| JP (1) | JP6805172B2 (enExample) |
| KR (1) | KR20180002729A (enExample) |
| CN (1) | CN107735088B (enExample) |
| AU (1) | AU2016258188B2 (enExample) |
| CA (1) | CA2984618C (enExample) |
| EA (1) | EA036965B1 (enExample) |
| IL (1) | IL255448B2 (enExample) |
| MX (1) | MX378983B (enExample) |
| WO (1) | WO2016179554A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107735088B (zh) * | 2015-05-07 | 2021-11-02 | Chdi基金会股份有限公司 | 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 |
| WO2016179550A1 (en) | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| JP2019528252A (ja) * | 2016-07-22 | 2019-10-10 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物オキサジアゾール誘導体 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CN109627207A (zh) * | 2018-12-17 | 2019-04-16 | 天津药明康德新药开发有限公司 | 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法 |
| WO2022174193A1 (en) * | 2021-02-15 | 2022-08-18 | The Research Foundation For The State University Of New York | Radiolabeled compositions and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061638A2 (en) | 2004-12-10 | 2006-06-15 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| SG182401A1 (en) | 2010-01-13 | 2012-08-30 | Tempero Pharmaceuticals Inc | Compounds and methods |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2013008162A1 (en) * | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| EA032526B1 (ru) * | 2011-08-30 | 2019-06-28 | Схди Фаундейшн, Инк. | Применение ингибитора кинуренин-3-монооксигеназы для лечения заболеваний и состояний, опосредованных активностью кинуренин-3-монооксигеназы |
| WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CA2856334A1 (en) * | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| MX2014011946A (es) * | 2012-04-05 | 2014-12-08 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. |
| WO2016179550A1 (en) | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| CN107735088B (zh) * | 2015-05-07 | 2021-11-02 | Chdi基金会股份有限公司 | 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 |
| RU2695227C9 (ru) | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| WO2017018803A1 (en) | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| CA2994688C (en) | 2015-08-04 | 2020-11-03 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
-
2016
- 2016-05-06 CN CN201680040061.8A patent/CN107735088B/zh active Active
- 2016-05-06 CA CA2984618A patent/CA2984618C/en active Active
- 2016-05-06 EA EA201792247A patent/EA036965B1/ru not_active IP Right Cessation
- 2016-05-06 AU AU2016258188A patent/AU2016258188B2/en active Active
- 2016-05-06 JP JP2017557324A patent/JP6805172B2/ja active Active
- 2016-05-06 WO PCT/US2016/031335 patent/WO2016179554A1/en not_active Ceased
- 2016-05-06 MX MX2017014300A patent/MX378983B/es unknown
- 2016-05-06 KR KR1020177034461A patent/KR20180002729A/ko not_active Withdrawn
- 2016-05-06 EP EP16790203.0A patent/EP3291810B1/en active Active
- 2016-05-06 US US15/148,907 patent/US10053434B2/en active Active
-
2017
- 2017-11-06 IL IL255448A patent/IL255448B2/en unknown
-
2018
- 2018-07-26 US US16/046,254 patent/US20190202795A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107735088B (zh) | 2021-11-02 |
| US20190202795A1 (en) | 2019-07-04 |
| WO2016179554A1 (en) | 2016-11-10 |
| EP3291810B1 (en) | 2022-08-10 |
| EP3291810A1 (en) | 2018-03-14 |
| CN107735088A (zh) | 2018-02-23 |
| AU2016258188A1 (en) | 2017-11-23 |
| EP3291810A4 (en) | 2018-11-07 |
| CA2984618A1 (en) | 2016-11-10 |
| IL255448B2 (en) | 2023-07-01 |
| MX378983B (es) | 2025-03-10 |
| MX2017014300A (es) | 2018-08-09 |
| AU2016258188B2 (en) | 2021-08-26 |
| EA036965B1 (ru) | 2021-01-20 |
| IL255448B1 (en) | 2023-03-01 |
| KR20180002729A (ko) | 2018-01-08 |
| CA2984618C (en) | 2024-01-09 |
| HK1252487A1 (en) | 2019-05-24 |
| BR112017023711A2 (pt) | 2018-07-17 |
| EA201792247A1 (ru) | 2018-06-29 |
| US20160326124A1 (en) | 2016-11-10 |
| IL255448A0 (en) | 2017-12-31 |
| US10053434B2 (en) | 2018-08-21 |
| JP2018515489A (ja) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6782255B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| JP7644517B2 (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| JP6805172B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| BR112014030655B1 (pt) | compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende | |
| KR20180110132A (ko) | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 | |
| CN120077051A (zh) | Kras抑制剂 | |
| MX2013008629A (es) | Inhibidores de histona desacetilasa y composiciones y metodos para su uso. | |
| EP2976341A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| CN109641894B (zh) | 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法 | |
| TW201514135A (zh) | 組蛋白去乙醯酶抑制劑及組成物，暨其使用之方法 | |
| CN113754635A (zh) | 稠环类化合物及其制备方法和用途 | |
| CN119546607A (zh) | Lrrk2抑制剂 | |
| HK1252487B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| BR112017023711B1 (pt) | Inibidores de histona deacetilase e composições e métodos de uso dos mesmos | |
| WO2020207352A1 (zh) | 三嗪酮并咪唑类化合物及其医药用途 | |
| HK1252489B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190507 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200407 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201001 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201001 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201009 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201013 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6805172 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |